爱美医疗 FOLD 深 沪
等待开盘 02-07 09:30:00 美东时间
14.29
+0.010
+0.07%
华盛通- 最 高14.38
- 今 开14.30
- 成交量 2306.44万股
- 最 低 14.18
- 昨 收 14.28
- 总市值 400.12万
- 52周最高 14.38
- 市盈率 静 --
- 换手率 8237.27%
- 52周最低 5.51
- 委 比 99.85%
- 总股本 0.00亿
- 历史最高 25.39
- 量 比 3.58
- 振 幅 1.40%
- 历史最低 1.10
- 每 手 1
- 风险率 2.51%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nasdaq Surges Over 1%; Lamb Weston Shares Decline Following Q2 Results
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gai...
2025-12-20 01:16
BioMarin Boosts Rare Disease Portfolio With Amicus Buyout, Stocks Rally
BioMarin acquires Amicus for $4.8B, expanding its rare disease portfolio with Fabry and Pompe therapies, in a deal expected to close Q2 2026.
2025-12-20 00:07
小米MIX Fold 3仅3828元
目前这款产品在京东售价5469.01元，在拍易得最新一期的活动中成交价仅3828元，浏览器访问拍易得官网可获得最新详情！ 小米MIX Fold 3 5G折叠屏手...
2025-10-20 09:22
苹果继任计划：约翰·特努斯有望接替蒂姆·库克
10月6日消息，据外电报道，有没有想过，一旦蒂姆·库克卸任，谁将引领苹果实现下一个重大创新？随着公司的发展，内部消息指出，一位领跑者已经显而易见。彭博社的马克...
2025-10-06 07:14
苹果下场OLED折叠手机，最受益的屏厂竟是他？
近期消息，天风国际证券分析师郭明錤最新发文透露，苹果公司将于明年发布折叠屏iPhone，与iPhone 18同系列，可能会命名为iPhone 18 Fold。市...
2025-08-22 10:23
单日暴涨130%+，肾病领域再成行业焦点
转自：新康界 4月30日，诺华公司宣布以17亿美元收购美股上市医药公司Regulus(NASDAQ:RGLS)，受此消息影响，Regulus的股价...
2025-06-23 19:50
New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve
Amicus Therapeutics announced a post-hoc analysis of the PROPEL study, showing cipaglucosidase alfa-atga + miglustat (cipa+mig) improved or stabilized most outcomes in late-onset Pompe disease (LOPD) patients switching from alglucosidase alfa, while those remaining on the comparator generally worsened or stabilized.
2025-06-03 11:00
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025
Amicus Therapeutics announced that its management will participate in two upcoming investor conferences in June 2025: the Jefferies Global Healthcare Conference in New York on June 4, and the Goldman Sachs Global Healthcare Conference in Miami on June 10. Webcasts of the presentations will be available on the company's investor website.
2025-05-30 11:00
Jefferies Initiates Coverage On Amicus Therapeutics with Buy Rating, Announces Price Target of $18
Jefferies analyst Dennis Ding initiates coverage on Amicus Therapeutics (NASDAQ:FOLD) with a Buy rating and announces Price Target of $18.
2024-09-06 20:05
